ClinicalTrials.gg
CompletedNCT00174252Updated Jun 15, 2010Results posted

Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age

A Phase 3 interventional study of Genotonorm (Somatropin) in Fetal Growth Retardation, sponsored by Pfizer. Completed at 22 sites in France. Open to participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2010-06-15.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
4 Years to 9 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 29 studies in Fetal Growth Retardation with a site in France — 8 open to participants now, 8 under way, 2 of them phase 3. Fetal Growth Retardation · France.

Enrollment
15th of 16
57 · median 207
Started
2005
the only one that year
Phase 3
7 of 29
2 open now
Registered
1st of 29
by date
Lead sponsor
2 of 29
Pfizer

Among the 29 studies in Fetal Growth Retardation with a site in France, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2005, is one of 7 in phase 3, and was the 1st registered.

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

Browse Fetal Growth Retardation studies →

Open to participants now

8 of the 29 studies in Fetal Growth Retardation with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.

This study: 4 Years to 9 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Fetal Growth Retardation with a site in France, or all of them as a file.
02

Study summary

To estimate the percentage of children with serum IGF-1 > 2 standard deviation (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment.

03

Conditions studied

  • Fetal Growth Retardation
04

Who can participate

Ages eligible
4 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronological age between 4 and 9 years for a boy and 4 and 7 years for a girl.
  • Measured Height \< -2.5 Standard Deviation

Exclusion criteria

Exclusion Criteria:

  • Pubertal signs ie: testis volume > or = 4 ml in boys and breast stage > or = B2 (Tanner)
  • Serious chronic disease (diabetes, renal insufficiency, heart failure, hepatic insufficiency, neoplasia)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Genotonorm (Somatropin)

    Drug: Genotonorm (Somatropin)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Children With Insulin Growth Factor-1 (IGF-1) > 2 Standard Deviation (SD) at 9 and 12 Months

    Percentage of children with serum IGF-1 \> 2 SD (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment. 9 months and 12 months are combined.

    Time frame: 9 and 12 months

Secondary outcomes

  1. Change in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    The height in SD was calculated using Sempe reference means and standard deviations for height. Change in height SD was calculated as height in SD at "12 months" minus height in SD at "Baseline".

    Time frame: Baseline, 12 months

  2. Change in Height SD CA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "24 months" minus height in SD at "Baseline".

    Time frame: Baseline, 24 months

  3. Change in Height SD CA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

    The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 or 24 months" minus height in SD at "Baseline".

    Time frame: Baseline, 12 and 24 months

  4. Change in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 months" minus height in SD at "Baseline".

    Time frame: Baseline, 12 months

  5. Change in Height SD BA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "24 months" minus height in SD at "Baseline".

    Time frame: Baseline, 24 months

  6. Change in Height SD BA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

    The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 or 24 months" minus height in SD at "Baseline".

    Time frame: Baseline, 12 and 24 months

  7. Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    Growth rate SD CA at 12 months was calculated as:(Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months Growth rate SD CA at 24 months was calculated as:(Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months

    Time frame: 12 and 24 months

  8. Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

    Growth rate SD CA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months Growth rate SD CA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months

    Time frame: 12 and 24 months

  9. Summary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for BA at 12 months

    Time frame: Baseline, 12 months

  10. Summary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for BA at 24 months

    Time frame: Baseline, 24 months

  11. Summary of Growth Rate SD (BA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

    Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for CA at 12 months Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for CA at 24 months

    Time frame: 12 and 24 months

  12. Analysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months

    Change in Height SD (CA) was calculated as: Height SD (CA) at 12 months minus Height SD (CA) at Baseline

    Time frame: Baseline, 12 months

  13. ANCOVA for Height SD CA at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months

    Height SD (CA) at 24 months.

    Time frame: Baseline, 24 months

  14. ANCOVA for Height SD BA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months

    Change in Height SD (BA) was calculated as: Height SD (BA) at 12 months minus Height SD (BA) at Baseline

    Time frame: Baseline, 12 months

  15. ANCOVA for Height SD BA at 24 Months in Children With IGF-1 <= 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months

    Height SD (BA) at 24 months

    Time frame: Baseline, 24 months

  16. Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    IGF-1 SD was calculated at each study time point using gender specific IGF-1 reference mean and SD for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 minus reference mean) divided by reference SD

    Time frame: 6, 9, 12, 15, 18, 21, and 24 months

  17. Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

    IGF-1 SD was calculated at each study time point using these gender specific IGF-1 reference means and SDs for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 - reference mean) / reference SD

    Time frame: 6, 9, 12, 15, 18, 21, and 24 months

  18. IGF-1/Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    Time frame: 12 and 24 months

  19. IGF-1/IGFBP-3 Ratio at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

    Time frame: 12 and 24 months

Other outcomes

  1. Change in Height From Baseline

    The standing height measurements were performed at the same time of the day by using a wallmounted device (e.g. Harpenden Stadiometer) at each study visit. The pre-specified clinical outcomes were analyzed at 12 and 24 months.

    Time frame: Baseline, 12 and 24 months

  2. Growth Rate at 12 and 24 Months

    Growth Rate was calculated at 12 months as: (Height at 12 months minus Height at Day 0) divided by {(Date of 12 months minus Date of Day 0) divided by 365.25} Growth Rate was calculated at 24 months as: (Height at 24 months minus Height at 12 months) divided by {(Date of 24 months minus Date of 12 months) divided by 365.25}

    Time frame: 12 and 24 months

  3. Summary of Body Mass Index (BMI) at 12 and 24 Months

    BMI was calculated at 12 months and 24 months as: (Weight at 12 or 24 months divided by Height at 12 or 24 months) squared

    Time frame: 12 and 24 months

  4. Change in BA From Baseline at 12 and 24 Months

    Change in BA was calculated as: (12 or 24 months minus Screening)

    Time frame: Baseline, 12 and 24 months

  5. BA/CA at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

    The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.

    Time frame: 12 and 24 months

  6. BA/CA at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

    The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.

    Time frame: 12 and 24 months

07

Results

Posted Jun 4, 2010

Participant flow

Participant flow — Overall Study
MilestoneGenotonorm
Started57
Completed55
Not completed2
Withdrew: Protocol violation2

Outcome measures

Other pre-specifiedChange in Height From Baseline

The standing height measurements were performed at the same time of the day by using a wallmounted device (e.g. Harpenden Stadiometer) at each study visit. The pre-specified clinical outcomes were analyzed at 12 and 24 months.

Time frame:
Baseline, 12 and 24 months
Reported as:
Mean · centimeters (cm)
Change in Height From Baseline
centimeters (cm)Genotonorm
12 Months9.0 ± 1.3
24 Months16.4 ± 2.2
PrimaryPercentage of Children With Insulin Growth Factor-1 (IGF-1) > 2 Standard Deviation (SD) at 9 and 12 Months

Percentage of children with serum IGF-1 \> 2 SD (compared to a child of the same gender and age and without growth hormone (GH) deficiency) 9 months and 12 months after initiation of GH treatment. 9 months and 12 months are combined.

Time frame:
9 and 12 months
Reported as:
Number · percentage of participants
Percentage of Children With Insulin Growth Factor-1 (IGF-1) > 2 Standard Deviation (SD) at 9 and 12 Months
percentage of participantsGenotonorm
No86.0
Yes14.0
Statistical analysis
  • Genotonorm · Percentage: 86.0 · 95% CI 74.2 to 93.795% CI was estimated using the F-distribution.
  • Genotonorm · Percentage: 14.0 · 95% CI 6.3 to 25.895% confidence interval (CI) was estimated using the F-distribution.
SecondaryChange in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

The height in SD was calculated using Sempe reference means and standard deviations for height. Change in height SD was calculated as height in SD at "12 months" minus height in SD at "Baseline".

Time frame:
Baseline, 12 months
Reported as:
Mean · SD for CA
Change in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
SD for CAGenotonorm
Change in Height SD Chronological Age (CA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months0.81 ± 0.26
SecondaryChange in Height SD CA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "24 months" minus height in SD at "Baseline".

Time frame:
Baseline, 24 months
Reported as:
Mean · SD for CA
Change in Height SD CA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
SD for CAGenotonorm
Change in Height SD CA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months1.24 ± 0.48
SecondaryChange in Height SD CA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 or 24 months" minus height in SD at "Baseline".

Time frame:
Baseline, 12 and 24 months
Reported as:
Mean · SD for BA
Change in Height SD CA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
SD for BAGenotonorm
12 Months1.13 ± 0.35
24 Months1.53 ± 0.20
SecondaryChange in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 months" minus height in SD at "Baseline".

Time frame:
Baseline, 12 months
Reported as:
Mean · SD for BA
Change in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
SD for BAGenotonorm
Change in Height SD Bone Age (BA) From Baseline at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months0.44 ± 1.34
SecondaryChange in Height SD BA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "24 months" minus height in SD at "Baseline".

Time frame:
Baseline, 24 months
Reported as:
Mean · Height in SD
Change in Height SD BA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
Height in SDGenotonorm
Change in Height SD BA From Baseline at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months0.12 ± 1.86
SecondaryChange in Height SD BA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

The height in SD was calculated using Sempe reference means and SDs for height. Change in height SD was calculated as height in SD at "12 or 24 months" minus height in SD at "Baseline".

Time frame:
Baseline, 12 and 24 months
Reported as:
Mean · SD for BA
Change in Height SD BA From Baseline at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
SD for BAGenotonorm
12 Months0.64 ± 1.19
24 Months0.64 ± 1.30
Other pre-specifiedGrowth Rate at 12 and 24 Months

Growth Rate was calculated at 12 months as: (Height at 12 months minus Height at Day 0) divided by {(Date of 12 months minus Date of Day 0) divided by 365.25} Growth Rate was calculated at 24 months as: (Height at 24 months minus Height at 12 months) divided by {(Date of 24 months minus Date of 12 months) divided by 365.25}

Time frame:
12 and 24 months
Reported as:
Mean · cm/year
Growth Rate at 12 and 24 Months
cm/yearGenotonorm
12 Months9.06 ± 1.40
24 Months (n=55)7.23 ± 1.38
SecondarySummary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

Growth rate SD CA at 12 months was calculated as:(Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months Growth rate SD CA at 24 months was calculated as:(Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months

Time frame:
12 and 24 months
Reported as:
Mean · SD for CA
Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
SD for CAGenotonorm
12 Months3.77 ± 1.68
24 Months (n=47)1.74 ± 1.51
SecondarySummary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

Growth rate SD CA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for CA at 12 months) divided by reference SD for CA at 12 months Growth rate SD CA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for CA at 24 months) divided by reference SD for CA at 24 months

Time frame:
12 and 24 months
Reported as:
Mean · SD for CA
Summary of Growth Rate SD (CA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
SD for CAGenotonorm
12 Months5.24 ± 1.64
24 Months2.15 ± 2.21
SecondarySummary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for BA at 12 months

Time frame:
Baseline, 12 months
Reported as:
Mean · SD for CA
Summary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
SD for CAGenotonorm
Summary of Growth Rate SD (BA) at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months2.38 ± 1.88
SecondarySummary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for BA at 24 months

Time frame:
Baseline, 24 months
Reported as:
Mean · SD for BA
Summary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
SD for BAGenotonorm
Summary of Growth Rate SD (BA) at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months1.26 ± 1.62
SecondarySummary of Growth Rate SD (BA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

Growth rate SD BA at 12 months was calculated as: (Growth rate at 12 months minus reference mean for BA at 12 months) divided by reference SD for CA at 12 months Growth rate SD BA at 24 months was calculated as: (Growth rate at 24 months minus reference mean for BA at 24 months) divided by reference SD for CA at 24 months

Time frame:
12 and 24 months
Reported as:
Mean · SD for BA
Summary of Growth Rate SD (BA) at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
SD for BAGenotonorm
12 Months4.02 ± 2.37
24 Months (n=6)1.71 ± 2.26
Other pre-specifiedSummary of Body Mass Index (BMI) at 12 and 24 Months

BMI was calculated at 12 months and 24 months as: (Weight at 12 or 24 months divided by Height at 12 or 24 months) squared

Time frame:
12 and 24 months
Reported as:
Mean · kg/meters squared (m2)
Summary of Body Mass Index (BMI) at 12 and 24 Months
kg/meters squared (m2)Genotonorm
12 Months (n=54)14.7 ± 1.5
24 Months (n=55)14.9 ± 1.4
SecondaryAnalysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months

Change in Height SD (CA) was calculated as: Height SD (CA) at 12 months minus Height SD (CA) at Baseline

Time frame:
Baseline, 12 months
Reported as:
Mean · SD for CA
Analysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months
SD for CAGenotonorm (IGF-1 < = 2 SD at 9 or 12 Months)Genotonorm (IGF-1 > 2 SD at 9 and 12 Months)
Analysis of Covariance (ANCOVA) for Height SD CA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months-1.94 ± 0.04-1.59 ± 0.10
Statistical analysis
  • Genotonorm (IGF-1 < = 2 SD at 9 or 12 Months) vs Genotonorm (IGF-1 > 2 SD at 9 and 12 Months) · ANCOVA · p = 0.002 · Mean difference (net): -0.35Adjusted for height SD at baseline.
SecondaryANCOVA for Height SD CA at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months

Height SD (CA) at 24 months.

Time frame:
Baseline, 24 months
Reported as:
Mean · SD for CA
ANCOVA for Height SD CA at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months
SD for CAGenotonorm (IGF-1 < = 2 SD at 9 or 12 Months)Genotonorm (IGF-1 > 2 SD at 9 and 12 Months)
ANCOVA for Height SD CA at 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months-1.53 ± 0.06-1.18 ± 0.14
Statistical analysis
  • Genotonorm (IGF-1 < = 2 SD at 9 or 12 Months) vs Genotonorm (IGF-1 > 2 SD at 9 and 12 Months) · ANCOVA · p = 0.023 (Bilateral test multiple comparison threshold for statistical significance = 0.05) · Mean difference (net): -0.35Adjusted for height SD at baseline.
SecondaryANCOVA for Height SD BA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months

Change in Height SD (BA) was calculated as: Height SD (BA) at 12 months minus Height SD (BA) at Baseline

Time frame:
Baseline, 12 months
Reported as:
Mean · SD for BA
ANCOVA for Height SD BA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months
SD for BAGenotonorm (IGF-1 < = 2 SD at 9 or 12 Months)Genotonorm (IGF-1 > 2 SD at 9 and 12 Months)
ANCOVA for Height SD BA at 12 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months0.56 ± 0.220.76 ± 0.48
Statistical analysis
  • Genotonorm (IGF-1 < = 2 SD at 9 or 12 Months) vs Genotonorm (IGF-1 > 2 SD at 9 and 12 Months) · ANCOVA · p = 0.708 · Mean difference (final values): -0.20Adjusted for height SD at baseline.
SecondaryANCOVA for Height SD BA at 24 Months in Children With IGF-1 <= 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months

Height SD (BA) at 24 months

Time frame:
Baseline, 24 months
Reported as:
Mean · SD for BA
ANCOVA for Height SD BA at 24 Months in Children With IGF-1 <= 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months
SD for BAGenotonorm (IGF-1 < = 2 SD at 9 or 12 Months)Genotonorm (IGF-1 > 2 SD at 9 and 12 Months)
ANCOVA for Height SD BA at 24 Months in Children With IGF-1 <= 2 SD at 9 or 12 Months and IGF-1 > 2 SD at 9 and 12 Months0.05 ± 0.250.64 ± 0.53
Statistical analysis
  • Genotonorm (IGF-1 < = 2 SD at 9 or 12 Months) vs Genotonorm (IGF-1 > 2 SD at 9 and 12 Months) · ANCOVA · p = 0.325 · Mean difference (net): -0.59Adjusted for height SD at baseline.
Other pre-specifiedChange in BA From Baseline at 12 and 24 Months

Change in BA was calculated as: (12 or 24 months minus Screening)

Time frame:
Baseline, 12 and 24 months
Reported as:
Mean · year
Change in BA From Baseline at 12 and 24 Months
yearGenotonorm
12 Months (n=33)1.2 ± 0.9
24 Months (n=31)2.5 ± 1.1
Other pre-specifiedBA/CA at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.

Time frame:
12 and 24 months
Reported as:
Mean · ratio
BA/CA at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
ratioGenotonorm
12 Months0.74 ± 0.17
24 Months0.82 ± 0.16
Other pre-specifiedBA/CA at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

The BA/CA ratio was calculated at Screening, 12 and 24 months. The CA was the age on the date that the corresponding BA X-ray was performed.

Time frame:
12 and 24 months
Reported as:
Mean · ratio
BA/CA at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
ratioGenotonorm
12 Months0.80 ± 0.21
24 Months0.83 ± 0.09
SecondarySummary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months

IGF-1 SD was calculated at each study time point using gender specific IGF-1 reference mean and SD for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 minus reference mean) divided by reference SD

Time frame:
6, 9, 12, 15, 18, 21, and 24 months
Reported as:
Mean · SD
Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
SDGenotonorm
6 Months (n=49)0.65 ± 1.11
9 Months (n=46)0.93 ± 1.26
12 Months (n=44)1.04 ± 0.96
15 Months (n=40)0.88 ± 1.28
18 Months (n=43)0.88 ± 1.17
21 Months (n=41)0.82 ± 0.93
24 Months (n=45)0.85 ± 1.17
SecondarySummary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months

IGF-1 SD was calculated at each study time point using these gender specific IGF-1 reference means and SDs for the CA of the child on the date of the corresponding IGF-1 blood sample: IGF-1 SD = (IGF-1 - reference mean) / reference SD

Time frame:
6, 9, 12, 15, 18, 21, and 24 months
Reported as:
Mean · SD
Summary of IGF-1 SD at 6, 9, 12, 15, 18, 21, and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
SDGenotonorm
6 Months (n=7)2.32 ± 0.68
9 Months (n=6)2.35 ± 0.19
12 Months (n=8)2.50 ± 0.27
15 Months (n=7)1.40 ± 1.08
18 Months (n=7)2.12 ± 1.18
21 Months (n=7)1.82 ± 1.09
24 Months (n=8)1.81 ± 1.03
SecondaryIGF-1/Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
Time frame:
12 and 24 months
Reported as:
Mean · ratio
IGF-1/Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio at 12 and 24 Months in Children With IGF-1 < = 2 SD at 9 or 12 Months
ratioGenotonorm
12 Months (n=44)0.17 ± 0.06
24 Months (n=45)0.19 ± 0.07
SecondaryIGF-1/IGFBP-3 Ratio at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
Time frame:
12 and 24 months
Reported as:
Mean · ratio
IGF-1/IGFBP-3 Ratio at 12 and 24 Months in Children With IGF-1 > 2 SD at 9 and 12 Months
ratioGenotonorm
12 Months0.23 ± 0.03
24 Months0.21 ± 0.06

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Genotonorm—6/57 (10.5%)30/57 (52.6%)
Most frequent serious events
Most frequent serious events
EventGenotonorm
Amniotic band syndromeCongenital, familial and genetic disorders1/57
DeafnessEar and labyrinth disorders1/57
PneumoniaInfections and infestations1/57
Staphylococcal infectionInfections and infestations1/57
DysuriaRenal and urinary disorders1/57
HaematuriaRenal and urinary disorders1/57
PleurisyRespiratory, thoracic and mediastinal disorders1/57
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders1/57
Most frequent other events
Showing 10 of 49
Most frequent other events
EventGenotonorm
VaricellaInfections and infestations6/57
BronchitisInfections and infestations5/57
HeadacheNervous system disorders5/57
ConstipationGastrointestinal disorders4/57
NasopharyngitisInfections and infestations4/57
RhinitisInfections and infestations4/57
Ear infectionInfections and infestations3/57
GastroenteritisInfections and infestations3/57
Insulin-like growth factor increasedInvestigations3/57
CoughRespiratory, thoracic and mediastinal disorders3/57

Baseline characteristics

Age, Customized
Age, Customized(participants)Genotonorm
<4 years1
Between 4 and 8 years49
Between 8 and 12 years7
>=12 years0
Sex: Female, Male
Sex: Female, Male(Participants)Genotonorm
Female34
Male23
08

Study locations

22 sites
  • Pfizer Investigational Site
    Amiens, 80030, France
  • Pfizer Investigational Site
    ANGERS Cedex 03, 49000, France
  • Pfizer Investigational Site
    Besançon, 25030, France
  • Pfizer Investigational Site
    Bordeaux, 33000, France
  • Pfizer Investigational Site
    Bron Cedex, 69677, France
  • Pfizer Investigational Site
    Caen Cedex 5, 14033, France
  • Pfizer Investigational Site
    Dunkerque Cedex 1, 59385, France
  • Pfizer Investigational Site
    Lille, 59019, France
  • Pfizer Investigational Site
    Limoges Cedex, 87042, France
  • Pfizer Investigational Site
    Lorient, France
  • Pfizer Investigational Site
    Nice, 06202, France
  • Pfizer Investigational Site
    PARIS Cedex 19, 75935, France
  • Pfizer Investigational Site
    Paris, 75571, France
  • Pfizer Investigational Site
    Paris, 75743, France
  • Pfizer Investigational Site
    Rennes, 35203, France
  • Pfizer Investigational Site
    Rouen, 76000, France
  • Pfizer Investigational Site
    Strasbourg, 67098, France
  • Pfizer Investigational Site
    Tarbes, 65000, France
  • Pfizer Investigational Site
    Toulouse, 31000, France
  • Pfizer Investigational Site
    Toulouse, 31026, France
  • Pfizer Investigational Site
    Tours, 37044, France
  • Pfizer Investigational Site
    Vandoeuvre Les Nancy, 54511, France
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Feb 2005
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Jun 4, 2010
Last update
Jun 15, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00174252
Lead sponsor
Pfizer
First posted
Sep 15, 2005
Start date
Feb 2005
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Jun 4, 2010
Last update
Jun 15, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion